Co-organized by Drs. Nevan Krogan, Brian Shoichet and Molly Shoichet, the Quantitative Biosciences Institute (QBI) at the University of California, Francisco and PRiME Next-Generation Precision Medicine at the University of Toronto present a joint symposium on "Quantitative Approaches to Drug Discovery and Precision Medicine" in San Francisco on November 8, 2024.
QBI seeks transformative results in biomedicine by supporting fundamental quantitative research in the biological sciences through significant collaborative efforts. PRiME is an institutional strategic initiative at the University of Toronto, dedicated to addressing unmet needs and challenges in drug discovery, diagnostics, and disease biology. PRiME brings together a powerful continuum of world-class basic and clinical scientists, biomedical engineers, innovators, and entrepreneurs, fostering seamless collaborations with Toronto’s precision medicine ecosystem and global partners.
The symposium aims to build collaborative relationships between scientists from both institutions. The intersection of drug discovery and personalized medicine with quantitative biology, machine learning and artificial intelligence opens new opportunities for discovery and training, ultimately leading to translation and new therapeutics for improved human health.
The event will highlight cutting edge research with a view towards a partnership between QBI and PRiME.
Event agenda
| 8:30 – 9:00 AM | Doors Open (Registrations + Breakfast) |
| 9:00 – 9:03 AM | Opening Remarks by Canadian Consul General - Rana Sarkar |
| 9:03 – 9:13 AM | Welcome: Nevan Krogan & Molly Shoichet |
Session I - Computational Modeling
(15 mins Talk + 5 mins Q/A)
Session Chair: Nevan Krogan
| 9:15 AM | Tanja Kortemme (QBI) | Deep-learning guided design of de novo proteins and controllable dynamics |
| 9:35 AM | Gary Bader (PRiME) | Multiscale and multimodal mapping of biology using AI |
| 9:55 AM | Michael Brudno (PRiME) | Healthcare data in the age of AI |
| 10:15 AM | Lani Wu (QBI) | AI in the loop for complex diseases (ALS): Disease stratification and patient care |
10:35 – 11:00 AM: 10:35 – 11:00 AM: Break (25 minutes)
Session II - Chemical Probes & Drug Discovery
(15 mins Talk + 5 mins Q/A)
Session Chair: Molly Shoichet
| 11:05 AM | Cheryl Arrowsmith (PRiME/SGC) | Probing the human proteome for therapeutic opportunities |
| 11:25 AM | Brian Shoichet (QBI) | A frustrated landscape for ligand optimization |
| 11:45 AM | Robert Batey (PRiME) | Small molecules and reactions for medicinal chemistry |
| 12:05 PM | Balyn Zaro (QBI) | Macrophages redeploy functional cancer cell surface proteins following phagocytosis |
| 12:25 PM | Carolyn Cummins (PRiME) | Development of LXRβ antagonists to treat steroid-induced diabetes and obesity |
12:45 – 1:45pm Lunch (1 hour)
Session III: Translation
(15 mins Talk + 5 mins Q/A)
Session Chair: Rob Rottapel
| 1:50 PM | Matthew State (QBI) | Advancing therapeutic opportunities in profound autism |
| 2:10 PM | Nevan Krogan (QBI) | Using systems approaches to understand disease mechanisms |
| 2:30 PM | David Uehling (PRiME/OICR) | OICR’s drug discovery program: recent innovations |
| 2:50 PM | Molly Shoichet (PRiME) | Going beyond 2D: Using 3D for target and drug discovery |
| 3:10 PM | James Fraser (QBI) | The SARS CoV 2 macrodomain and how to inhibit it |
3:30 – 3:45pm: Break (15 minutes)
VC Panel: Current Opportunities & Challenges for Company Formation in Drug Discovery
| 3:50 PM – 4:40 PM | VC Panel: Current Opportunities & Challenges for Company Formation in Drug Discovery Douglas Crawford (Mission Bay Capital) Rami Hannoush (Versant Ventures) Spiros Liras (Apple Tree Partners) Craig Muir (Third Rock Ventures) Alison Nankivell (MaRS Discovery District) Greg Yap (Menlo Ventures) Moderator: Brian Shoichet (QBI) |
| 4:40 PM – 4:45 PM | Closing Remarks:Brian Shoichet (QBI) |